Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles

被引:20
作者
Carruthers, Alastair [1 ]
Carruthers, Jean [2 ]
Fagien, Steven
Lei, Xiaofang [3 ]
Kolodziejczyk, Julia [3 ]
Brin, Mitchell F. [3 ,4 ]
机构
[1] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada
[3] Allergan Plc, Dept Clin Dev, Irvine, CA 92612 USA
[4] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA
关键词
TOXIN TYPE-A; BOTULINUM-TOXIN; DOUBLE-BLIND; EFFICACY; THERAPY; SAFETY; BOTOX;
D O I
10.1097/DSS.0000000000000704
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUNDOnabotulinumtoxinA has demonstrated the ability to eliminate mild glabellar lines at rest; however, less is known regarding the effect of repeat treatment on more severe lines at rest.OBJECTIVETo assess the effect of repeated onabotulinumtoxinA treatment for reduction of glabellar lines at rest.METHODSSubjects 18 to 75 years old with at least mild glabellar lines at rest, as assessed by the validated Facial Wrinkle Scale (FWS) with photonumeric guide (score 1), received 3 treatments of 20 U onabotulinumtoxinA 4 months apart (N = 225). Response was defined as elimination of glabellar lines at rest (FWS score = 0) at any time point (Days 7, 30, 60, 90, and 120). Effect of treatment cycle on response was analyzed using repeated measures logistic regressions (p < .05).RESULTSMost subjects were female (85%) and white (88%) (age range: 35-54 years). The likelihood of significant response was as follows: for all subjects combined (odds ratio [OR]: 1.31), for subjects with mild resting lines at baseline (OR: 1.49), and for older women (55 years) with mild resting lines at baseline (OR: 2.22). Of all subjects, 76% responded after 1 treatment, and 45% responded in all 3 cycles.CONCLUSIONSubjects repeatedly treated with onabotulinumtoxinA showed progressive improvement in glabellar lines at rest.
引用
收藏
页码:1094 / 1101
页数:8
相关论文
共 21 条
  • [1] Beer K, 2006, COSMET DERMATOL, V19, P567
  • [2] Bonaparte JP, 2014, OTOLARYNGOL HEAD N S, V149, P41
  • [3] Botulinum toxin type A products are not interchangeable: a review of the evidence
    Brin, Mitchell F.
    James, Charmaine
    Maltman, John
    [J]. BIOLOGICS-TARGETS & THERAPY, 2014, 8 : 227 - 240
  • [4] Carruthers A, 2004, J Clin Res, V7, P1
  • [5] Eyebrow height after botulinum toxin type A to the glabella
    Carruthers, Alastair
    Carruthers, Jean
    [J]. DERMATOLOGIC SURGERY, 2007, 33 : S26 - S31
  • [6] OnabotulinumtoxinA Treatment of Mild Glabellar Lines in Repose
    Carruthers, Alastair
    Carruthers, Jean
    Lei, Xiaofang
    Pogoda, Janice M.
    Eadie, Nina
    Brin, Mitchell F.
    [J]. DERMATOLOGIC SURGERY, 2010, 36 (04) : 2168 - 2171
  • [7] A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines
    Carruthers, JA
    Lowe, NJ
    Menter, MA
    Gibson, J
    Nordquist, M
    Mordaunt, J
    Walker, P
    Eadie, N
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) : 840 - 849
  • [8] Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type a for patients with glabellar lines
    Carruthers, JD
    Lowe, NJ
    Menter, MA
    Gibson, J
    Eadie, N
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2003, 112 (04) : 1089 - 1098
  • [9] Botulinum toxin type A treatment of multiple upper facial sites: Patient-reported outcomes
    Carruthers, Jean
    Carruthers, Alastair
    [J]. DERMATOLOGIC SURGERY, 2007, 33 : S10 - S17
  • [10] Abo-, Inco-, Ona-, and Rima-Botulinum Toxins in Clinical Therapy: A Primer
    Chen, Jack J.
    Dashtipour, Khashayar
    [J]. PHARMACOTHERAPY, 2013, 33 (03): : 304 - 318